<DOC>
	<DOCNO>NCT02989402</DOCNO>
	<brief_summary>This multicenter , prospective , phase IV study evaluate safety , tolerability effectiveness rivastigmine 27 mg -15 cm2 transdermal patch prescribe patient severe dementia Alzheimer 's type per discretion treat physician .</brief_summary>
	<brief_title>A Phase IV Study Evaluate Safety , Tolerability Effectiveness Rivastigmine Patch 15cm2 Patients With Severe Dementia Alzheimer 's Type .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>1 . Patients willing participate study provide write informed consent . 2 . Patients diagnose severe dementia secondary Alzheimer 's disease ( AD ) 3 .Patient 's prescribed rivastigmine 27mg 15 cm2 transdermal patch per discretion treat physician 1 . Contraindication per PI 2 . Patients simultaneously participate study 3 . Use investigational drug within 5 halflives enrollment , within 30 day ( small molecule ) /until expect PD effect return baseline ( biologics ) ] , whichever longer . 4 . History hypersensitivity study drug drug similar chemical class</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer , Rivastigmine</keyword>
</DOC>